Choreo LLC Has $2.81 Million Stock Position in Haleon PLC Sponsored ADR (NYSE:HLN)

Choreo LLC cut its stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 11.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 273,219 shares of the company's stock after selling 35,325 shares during the period. Choreo LLC's holdings in Haleon were worth $2,811,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. HighPoint Advisor Group LLC increased its stake in Haleon by 9.0% in the first quarter. HighPoint Advisor Group LLC now owns 41,183 shares of the company's stock valued at $423,000 after purchasing an additional 3,415 shares in the last quarter. Bailard Inc. bought a new position in Haleon during the first quarter worth about $237,000. Cullen Frost Bankers Inc. lifted its holdings in Haleon by 99.5% during the first quarter. Cullen Frost Bankers Inc. now owns 6,291 shares of the company's stock worth $65,000 after acquiring an additional 3,137 shares in the last quarter. Leo Wealth LLC acquired a new position in Haleon in the first quarter valued at about $119,000. Finally, Apollon Wealth Management LLC increased its holdings in shares of Haleon by 5.4% in the first quarter. Apollon Wealth Management LLC now owns 21,722 shares of the company's stock worth $224,000 after acquiring an additional 1,111 shares in the last quarter. Institutional investors own 6.67% of the company's stock.

Haleon Stock Up 0.2%

Shares of HLN traded up $0.02 during mid-day trading on Friday, hitting $9.87. 9,878,220 shares of the company's stock were exchanged, compared to its average volume of 12,174,360. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.98 and a quick ratio of 0.78. Haleon PLC Sponsored ADR has a 52 week low of $8.86 and a 52 week high of $11.42. The company has a market cap of $44.32 billion, a PE ratio of 25.30, a P/E/G ratio of 2.86 and a beta of 0.25. The company has a 50-day simple moving average of $10.51 and a 200 day simple moving average of $10.18.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on HLN shares. Wall Street Zen lowered Haleon from a "buy" rating to a "hold" rating in a research report on Saturday, July 12th. Morgan Stanley raised shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price target on the stock in a research note on Friday, May 9th. Barclays reiterated an "overweight" rating on shares of Haleon in a report on Tuesday, May 6th. BNP Paribas raised shares of Haleon to a "strong-buy" rating in a research report on Tuesday, May 27th. Finally, BNP Paribas Exane upgraded shares of Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price objective on the stock in a report on Tuesday, May 27th. Six investment analysts have rated the stock with a hold rating, four have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Haleon presently has an average rating of "Moderate Buy" and a consensus target price of $12.33.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.